Advertisement

International Journal of Hematology

, Volume 101, Issue 4, pp 398–404 | Cite as

Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy

  • Haruhito Totani
  • Shigeru KusumotoEmail author
  • Takashi Ishida
  • Arisa Masuda
  • Takashi Yoshida
  • Asahi Ito
  • Masaki Ri
  • Hirokazu Komatsu
  • Shuko Murakami
  • Masashi Mizokami
  • Ryuzo Ueda
  • Akio Niimi
  • Hiroshi Inagaki
  • Yasuhito Tanaka
  • Shinsuke Iida
Original Article

Abstract

Reactivation of hepatitis B virus (HBV) infection may occur in adult T-cell leukemia–lymphoma (ATL) patients with resolved HBV infection who receive monotherapy with the anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab. However, there is little evidence regarding the incidence and characteristics of HBV reactivation in ATL patients receiving systemic chemotherapy, including the use of this antibody. We conducted a retrospective study for 24 ATL patients with resolved HBV infection underwent regular HBV DNA monitoring to assess HBV reactivation in Nagoya City University Hospital between January 2005 and June 2013. With median HBV DNA follow-up of 238 days (range 57–1420), HBV reactivation (defined as the detection of HBV DNA) was observed in three (12.5 %) of 24 patients with resolved HBV infection. No hepatitis due to HBV reactivation occurred in those patients who were diagnosed with HBV DNA levels below 2.1 log copies/mL and who received antiviral drugs. Mogamulizumab was administered prior to HBV reactivation in two of three HBV-reactivated patients. In the mogamulizumab era, further well-designed prospective studies are warranted to estimate the incidence of HBV reactivation and to establish regular HBV DNA monitoring-guided preemptive antiviral therapy for such patients.

Keywords

Reactivation HBV CCR4 Mogamulizumab ATL 

Abbreviations

HBV

Hepatitis B virus

ATL

Adult T-cell leukemia–lymphoma

HBsAg

Hepatitis B surface antigen

Anti-HBc

Antibodies against hepatitis B core antigen

Anti-HBs

Antibodies against hepatitis B surface antigen

CCR4

CC chemokine receptor 4

Notes

Acknowledgments

We would like to thank staff as follows: Ms. Chiori Fukuyama and Dr. Shintaro Ogawa (Nagoya City University Graduate School of Medical Sciences, Nagoya) for keeping and measurement of specimens on this study. We also thank Dr. Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd., Tokyo) for his enlightening advice on this article. This study was supported in part by the Ministry of Health, Labour and Welfare of Japan (grant-in-aid H24-kanen-004 to M.M.) and the Ministry of Education, Culture, Sports Science and Technology of Japan (grant-in-aid for Scientific Research (C) No. 24591428 to S.K.) and grant-in-aid for National Cancer Center Research and Development Fund (No. 26-A-4 to T.I.).

Conflict of interest

Shigeru Kusumoto received Research funding and honoraria from Kyowa Hakko Kirin Co., Ltd., and honoraria from Bristol-Myers Squibb. Takashi Ishida received research funding from Kyowa Hakko Kirin Co., Ltd., Bayer Pharma AG, and Celgene K.K. Ryuzo Ueda received research funding from Kyowa Hakko Kirin Co., Ltd. Yasuhito Tanaka received research funding from Bristol-Myers Squibb, and honoraria from Bristol-Myers Squibb. Shinsuke Iida received research funding from Kyowa Hakko Kirin Co., Ltd.

References

  1. 1.
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–8.PubMedGoogle Scholar
  2. 2.
    Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59–68.CrossRefPubMedGoogle Scholar
  3. 3.
    Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–11 (Epub 2008/12/17).CrossRefPubMedGoogle Scholar
  4. 4.
    Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90(1):13–23 (Epub 2009/06/23).CrossRefPubMedGoogle Scholar
  5. 5.
    Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol. 2011;46(1):9–16 (Epub 2010/10/07).CrossRefPubMedGoogle Scholar
  6. 6.
    Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310(16):1664.CrossRefPubMedGoogle Scholar
  7. 7.
    Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625–34.PubMedGoogle Scholar
  8. 8.
    Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–31.CrossRefPubMedGoogle Scholar
  9. 9.
    Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia–lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia–lymphoma. Int J Hematol. 2011;94(5):443–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia–lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Motohashi K, Suzuki T, Kishimoto K, Numata A, Nakajima Y, Tachibana T, et al. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2013;98(2):258–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Nakano N, Kusumoto S, Tanaka Y, Ishida T, Takeuchi S, Takatsuka Y, et al. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia–lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2014;44(3):354–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Shin IT, Tanaka Y, Tateno Y, Mizokami M. Development and public release of a comprehensive hepatitis virus database. Hepatol Res. 2008;38(3):234–43.CrossRefGoogle Scholar
  15. 15.
    Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59(6):2092–100.CrossRefPubMedGoogle Scholar
  16. 16.
    Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Prospective nationwide observational study of hepatitis B virus (HBV) DNA monitoring and preemptive antiviral therapy for HBV reactivation in patients with B-cell non-Hodgkin lymphoma following rituximab containing chemotherapy: results of interim analysis. Blood. 2012; 120(21):abstract 2641.Google Scholar
  17. 17.
    Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia–lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Jo T, Ishida T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia–lymphoma (ATL). J Clin Oncol 2013; 31: (suppl; abstr 8506).Google Scholar
  19. 19.
    Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci. 2011;102(1):44–50.CrossRefPubMedGoogle Scholar
  20. 20.
    Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42(7):627–36 Epub 2012/06/13.CrossRefPubMedGoogle Scholar
  21. 21.
    EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85 Epub 2012/03/23.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2015

Authors and Affiliations

  • Haruhito Totani
    • 1
  • Shigeru Kusumoto
    • 1
    Email author
  • Takashi Ishida
    • 1
  • Arisa Masuda
    • 1
  • Takashi Yoshida
    • 1
  • Asahi Ito
    • 1
  • Masaki Ri
    • 1
  • Hirokazu Komatsu
    • 1
  • Shuko Murakami
    • 2
  • Masashi Mizokami
    • 3
  • Ryuzo Ueda
    • 4
  • Akio Niimi
    • 5
  • Hiroshi Inagaki
    • 6
  • Yasuhito Tanaka
    • 2
  • Shinsuke Iida
    • 1
  1. 1.Department of Hematology and OncologyNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Department of Virology and Liver UnitNagoya City University Graduate School of Medical SciencesNagoyaJapan
  3. 3.The Research Center for Hepatitis and Immunology, National Center for Global Health and MedicineIchikawaJapan
  4. 4.Department of Tumor ImmunologyAichi Medical University School of MedicineAichiJapan
  5. 5.Department of Respiratory Medicine, Allergy and RheumatologyNagoya City University Graduate School of Medical SciencesNagoyaJapan
  6. 6.Department of Anatomic Pathology and Molecular DiagnosticsNagoya City University Graduate School of Medical SciencesNagoyaJapan

Personalised recommendations